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Abstract
Borrelia recurrentis, the etiologic agent of louse-borne relapsing fever in humans, has evolved strategies, including antigenic
variation, to evade immune defence, thereby causing severe diseases with high mortality rates. Here we identify for the first
time a multifunctional surface lipoprotein of B. recurrentis, termed HcpA, and demonstrate that it binds human complement
regulators, Factor H, CFHR-1, and simultaneously, the host protease plasminogen. Cell surface bound factor H was found to
retain its activity and to confer resistance to complement attack. Moreover, ectopic expression of HcpA in a B. burgdorferi
B313 strain, deficient in Factor H binding proteins, protected the transformed spirochetes from complement-mediated
killing. Furthermore, HcpA-bound plasminogen/plasmin endows B. recurrentis with the potential to resist opsonization and
to degrade extracellular matrix components. Together, the present study underscores the high virulence potential of B.
recurrentis. The elucidation of the molecular basis underlying the versatile strategies of B. recurrentis to escape innate
immunity and to persist in human tissues, including the brain, may help to understand the pathological processes
underlying louse-borne relapsing fever.
Citation: Grosskinsky S, Schott M, Brenner C, Cutler SJ, Kraiczy P, et al. (2009) Borrelia recurrentis Employs a Novel Multifunctional Surface Protein with Anti-
Complement, Anti-Opsonic and Invasive Potential to Escape Innate Immunity. PLoS ONE 4(3): e4858. doi:10.1371/journal.pone.0004858
Editor: David M. Ojcius, University of California Merced, United States of America
Received January 5, 2009; Accepted February 13, 2009; Published March 24, 2009
Copyright:  2009 Grosskinsky et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported, in part, by the Deutsche Forschungsgemeinschaft to RW (Wa 533/7-1 and Wa 533/8-1). The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: wallich@uni-hd.de
Introduction
B. recurrentis, the causative agent of louse-borne relapsing fever
(LBRF) is transmitted to humans, its reservoir host, by contam-
ination of abraded skin with either hemolymph or feces of an
infected human body louse (Pediculus humanus humanus) [1,2]. The
last century has seen multiple epidemics of LBRF in Europe, with
high mortality rates up to 40%. However, currently epidemic
outbreaks of LBRF are only reported from Africa [3,4]. LBRF is a
systemic inflammatory disease, characterized by one to five
relapses of fever and a massive spirochetemia [5]. If treated with
antibiotics, the mortality is reduced to 2–6%, however, patients
often suffer from Jarish-Herxheimer reactions [6].
In order to survive in human tissues, including the blood, B.
recurrentis has to escape innate and adaptive immune defence
processes. Complement acts as an important part of host innate
immunity, which is essential for recognition and elimination of
microbes. However, pathogenic organisms can evade complement
attack that is either mediated by the acquisition of host regulators
to the surface of the pathogen or by expression of endogenous
complement regulators [7]. An increasing number of pathogenic
microbes utilize host complement regulators for immune evasion
and for down-regulation of complement activation. In fact we and
others have recently demonstrated that tick-borne pathogens, B.
hermsii and B. burgdorferi, are able to bind complement regulatory
proteins, i.e. factor H (CFH), CFH-like protein 1 (CFHL-1) and
CFH-related protein 1 (CFHR-1), via their surface lipoproteins
CRASP-1, thereby conferring resistance to complement attack
[8,9,10,11,12]. Surface bound CFH controls complement activa-
tion by accelerating the decay of the C3 convertase of the
alternative pathway and by inactivating newly formed C3b
[13,14]. CFH represents the main human fluid phase regulator
of the alternative pathway of complement activation and belongs
to the factor H protein family, consisting of seven structurally
related proteins in humans, including Factor H-related proteins
(CFHRs) [15]. All factor H protein family members are composed
of short consensus repeats (SCRs) [16]. Among those, CFHR-1
was recently shown to inhibit complement activation by interfering
with C5 convertase and terminal complex formation (unpublished
data).
Another common strategy of pathogens to circumvent the
immune system and to persist is based on their capability to exploit
host plasma derived proteases, in particular human plasminogen/
plasmin (PLG) in order to breach tissue barriers. Recently, we
have identified and characterized a number of PLG-binding outer
surface lipoproteins in related spirochetes, including B. burgdorferi
and B. hermsii. B. burgdorferi was shown to bind PLG via a multitude
of lipoproteins, such as CRASP-3 (ErpP), CRASP-4 (ErpC),
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[17,18]. B. hermsii, on the other hand, was found to interact with
PLG via a 21-kDa lipoprotein, which also binds CFH via distinct,
non-overlapping domains [9]. Surface bound PLG is subsequently
processed via urokinase-type plasminogen activator (uPA) to active
plasmin, a broad-spectrum serine protease, capable of degrading
constituents of the extracellular matrix and basement membranes
[19,20]. The fact that surface-bound PLG retains its proteolytic
activity, even in the presence of serum inhibitors, suggests this
process as a suitable means of pathogens to readily disseminate
and to persist in the host.
CFH- and C4b-binding proteins of B. recurrentis have been
proposed [21], but so far these proteins have not been isolated.
Here we provide evidence that B. recurrentis express a novel
multifunctional surface lipoprotein, which by exploiting host
proteins confers resistance to both, complement attack and
opsonization and simultaneously acquires an increased potential
to invade host tissues.
Materials and Methods
Bacterial strains and growth conditions
Relapsing fever spirochetes B. recurrentis strain A1 and A17, B.
hermsii (ATCC35209) strain HS1 and the Lyme disease spirochete
B. burgdorferi strain B313, which is a clonal mutant of B31 lacking
all linear and circular plasmids with the exception of cp32-1, cp32-
2, cp32-4, cp26 and lp17, were cultivated in BSK-H complete
medium (PAN Biotech, Aidenbach, Germany) supplemented with
5% rabbit serum (Cell Concept, Freiburg, Germany) at 30uC [22].
Bacteria were harvested by centrifugation and washed with
phosphate-buffered saline. The density of spirochetes was
determined using dark-field microscopy and a Kova counting
chamber (Hycor Biomedical, Garden Grove, CA). E. coli JM109
were grown at 37uC in LB medium.
Isolation and cloning of HcpA, construction of expression
plasmids and production of recombinant proteins
Isolation of the CFH binding protein of B. recurrentis was carried
out by co-immunoprecipitation. Protein G sepharose beads
(Amersham Bioscience, Freiburg, Germany) were loaded with
polyclonal anti-factor H antibody (Calbiochem, Schwalbach,
Germany) and purified human factor H (Calbiochem). Subse-
quently, beads were incubated overnight at 4uC with whole cell
lysates of B. recurrentis A1. Immunoprecipitates were separated by
SDS-PAGE and visualized by staining with colloidal Coomassie
(Pierce/Thermofisher, Bonn, Germany). The selected protein
band of approximately 17 kDa was cored from the gel and
subjected to mass spectrometric analysis. The identified peptides
matched an open reading frame of 525 bp of the B. recurrentis A1
genome, designated hcpA.
The gene encoding HcpA was amplified by PCR using primers
BrF and BrR (Table 1), cloned into pGEM-T Easy vector
(Promega, Mannheim, Germany) and sequenced by using the
BigDye terminator cycle sequencing kit (PE Applied Biosystems).
The resulting plasmid pGEM-Br was used as template for
construction of expression plasmids by PCR amplification. For
recombinant full-length HcpA protein, primers BrBam and BrSal
were used, for N- and C-terminal deletion mutants, these primers
were applied in combination with D48Bam, D78Bam, D145Sal or
D115Sal (Table 1) resulting in recombinant proteins HcpA D48-
175, D78-175, D18-145 and D18-115, respectively. After digestion
with restriction enzymes BamHI and SalI, PCR fragments were
ligated in frame into the His6-tag encoding sequence into vector
pQE-30Xa (Qiagen, Hilden, Germany). For expression of N-
terminal His-tagged fusion proteins the plasmids were transformed
into E.coli strain JM109 and recombinant proteins were purified as
recommended by the manufacturer (Qiagen).
Expression of recombinant proteins of CFH, CFHL-1 and
CFHR-1
Deletion constructs of CFH (CFHSCR1-7, CFHSCR8-20,
CFHSCR15-20, CFHSCR15-19) and CFHR-1 were expressed in
Spodoptera frugiperda Sf9 insect cells infected with a recombinant
baculovirus. The cloning, expression and purification have been
described previously [14,23]. The CFH deletion mutant
CFHSCR19-20 was amplified by PCR, ligated in frame into pQE-
30Xa vector and expressed as fusion protein with an N-terminal
His6-tag. Expression and purification was done as recommended
by the manufacturer (Qiagen).
SDS-PAGE, Ligand affinity blot and ELISA
Borrelial whole cell lysates (15 mg) or purified recombinant
HcpA proteins (200 ng) were subjected to Tris/Tricine-SDS-
PAGE under reducing conditions and transferred to nitrocellulose
Table 1. Oligonucleotides used in this study.
Primer Sequence (59 to 39) purpose of use
BrF TTC AGA AGT GGA GCA ATC amplification of hcpA gene
BrR ACA TAA TAA ACG AAT TTT AAT CTA TG amplification of hcpA gene
BrBam CAT TAT TGG ATC CGA ACT CTT AAG C generation of expression plasmid
BrF1 AAA CAG GCT CAA TCA GCT C amplification of hcpA gene
BrR1 TCT AGA TCA TTA AAG TTT GCA G amplification of hcpA gene
BrSal ACA TAA TAA ACG TCG ACT AAT CTA TG generation of expression plasmid
D48Bam CAG GCT GGA TCC TTT TTT CAA GAA TC construction of deletion mutants
D78Bam AA GAT GGA TCC CAA AAG ACA TTA AAC construction of deletion mutants
D145Sal TA TAA GTC GAC TTA TAT AGA GTT TAT TG C construction of deletion mutants
D115Sal AA AGA GTC GAC TTA GAT AAA CTT TAT CG construction of deletion mutants
BrTBam TTC AGA AGT GGA TCC ATC construction of pBR
BrTSph GGT AAT TAA TTA TGC ATG CAA TAA TTA ATT ATT TCA AG construction of pBR
doi:10.1371/journal.pone.0004858.t001
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recombinant proteins, microtiter plates (MaxiSorp, Nunc) were
coated with HcpA or the deletion mutants (100 ml; 1 mg/ml) for
2 h at room temperature. The wells were washed with PBS/
0.05%Tween, blocked with PBS/5% BSA and incubated with
CFH (10 mg/ml), 50% normal human serum (NHS) or PLG
(20 mg/ml) for 1 h at RT. After washing, HcpA bound proteins
were detected by goat anti-CFH (Calbiochem) or goat anti-PLG
(Acris) antibodies or CFHR-1 specific mouse mAb JHD8 followed
by peroxidase-conjugated rabbit anti-goat IgG (Dianova) or sheep
anti-mouse secondary antibody (GE Healthcare), respectively.
Substrate reaction was performed with o-phenyldiamine dihydro-
chloride (Sigma-Aldrich) and absorbance was measured at
492 nm. For competition inhibition assay, HcpA (2 mg/ml) was
coated on microtiter plates. To analyze the ability of PLG to
inhibit the binding of CFH to HcpA, plates were incubated
simultaneously with constant amounts of CFH (3 mg/ml) and
different amounts of PLG (0.001–100 mg/ml). The ability of CFH
to inhibit the binding of PLG to HcpA was determined by adding
constant amounts of PLG (10 mg/ml) with different amounts of
CFH (0.001–100 mg/ml). HcpA bound CFH and PLG were
detected as described above. For detection of purified recombinant
HcpA full-length protein and deletion mutants, the anti His6-tag
monoclonal mouse antibody (Calbiochem) was used.
Immunofluorescence analysis
Spirochetes (1610
7) were washed with Tris buffer (30 mM Tris,
60 mM NaCl, pH 7.4) and incubated with mAb directed against
HcpA (BR-1) for 1 h at RT. For detection of CFH-binding cells
were treated with purified human CFH for 1 h at RT followed by
incubation with CFH-specific mAb JHD7. Spirochetes were then
washed with Tris buffer/0.1% BSA, spotted on coverslips and
allowed to air-dry for 1 h. After methanol fixation, samples were
dried for 15 min and incubated for 1 h in a humidified chamber
with Cy3-labeled rabbit anti-mouse IgG (1/200, Dianova). Cells
were visualized at a magnification of 10006using a Nikon Eclipse
90i upright automated microscope and images were obtained
using a Nikon DS-1 QM sensitive black and white CCD camera at
a resolution of 0.133 mm/pixel.
Flow cytometry
Briefly, 10
7 B. recurrentis A1 and A17, B. hermsii HS1 and B.
burgdorferi B313 cells were washed twice with PBS, blocked for
15 min at RT with PBS/10%BSA, and incubated with 10 mg/ml
of biotinylated CFH in FACS-buffer (PBS/1%BSA) for 1 h at RT.
As a negative control, spirochetes were incubated with same
concentration of biotinylated BSA. Cells were washed intensively
for three times and stained with phycoerythrin (PE) labeled
streptavidin (Bio-Rad). Cells were then fixed with 1% parafor-
maldehyde overnight and analyzed on a FACS-Calibur (BD
Biosciences) and CellQuest software (BD).
In situ protease treatment of spirochetes
Cells of B. recurrentis strain A1 were treated with proteases using
a modified, previously described method [25]. Briefly, intact
borrelial cells were incubated with either proteinase K or trypsin
and whole-cell protein preparations were separated by SDS-
PAGE (13%) as described [26].
Surface plasmon resonance analysis
Protein-protein interactions were analyzed using surface
plasmon resonance with a Biacore 3000 instrument (Biacore
AB), as described elsewhere [27].
Cofactor asssay
Cofactor activity of CFH bound to immobilized HcpA or intact
B. recurrentis A1 cells was analyzed by measuring factor I-mediated
conversion of C3b to inactive C3b (iC3b) [28].
Substrate assay for plasmin bound to spirochetes and
HcpA
Intact B. recurrentis A1 cells (1610
8) were incubated with 10 mg
PLG (Chromogenix) in the presence or absence of 100 mM
tranexamic acid for 30 min at 30uC in Eppendorf tubes. Following
two washes, B. recurrentis were resuspended in 50 ml assay buffer
(30 mM Tris, 60 mM NaCl, pH 7.4), transferred to microtiter
plates and uPA (25 ng, Chemicon Int., Hampshire, UK) as well as
plasmin substrate D-Val-Leu-Lys 4-nitroanilide dihydrochloride
(20 mg, S-2251, Sigma-Aldrich, Taufkirchen, Germany) was
added. The absorbance change at 405 nm was monitored for up
to 6 hours directly in the plates. Similarly, HcpA (0.2 mg) was
coated on microtiter plates and after blocking, PLG in the
presence or absence of 100 mM tranexamic acid was added,
incubated for 10 min at 37uC and experiment was carried out as
described above. For plasmin-dependent degradation of fibrino-
gen, HcpA (0.2 mg) coated microtiter plates were incubated with
PLG. Subsequently, fibrinogen (500 ng, Calbiochem) and uPA
(10 ng) were added and incubated at 37uC for 0.5, 1, 2, 4 and 6 h.
Reaction mixtures were then separated by SDS-PAGE, trans-
ferred to nitrocellulose and probed with rabbit anti-fibrinogen Ab
(Calbiochem) and peroxidase-conjugated goat anti-rabbit second-
ary antibody (Dianova) for detection of fibrinogen degradation
products.
C3b deposition and degradation on borrelial surface
Anti-opsonic properties of plasmin bound to the borrelial
surface were investigated by a C3b deposition and degradation
assay based on whole-cell ELISA. Intact B.recurrentis, B. burgdorferi
B313 and transformed B. burgdorferi B313/pBR spirochetes (10
7/
well) were washed, resuspended in PBS and immobilized onto
microtiter plates (MaxiSorp, Nunc) overnight at 4uC. After
washing with PBS/0.05%Tween, wells were blocked with PBS/
0.1% gelatine for 1 h at RT and incubated with 10% normal
human serum (NHS) for 30 min at 37uC. B. burgdorferi B313 and
B313/pBR were processed instantly, whereas B. recurrentis cells
were incubated with PLG (10 mg) in the presence or absence of the
lysine analogue tranexamic acid (TA); as a negative control, cells
were treated with buffer. Bound PLG was activated by uPA for 3 h
at 37uC. Deposited C3b was then detected by incubation with
biotinylated rabbit anti-human C3c IgG (Dako) followed by
peroxidase-conjugated streptavidin (Amersham Bioscience) and
analyzed as described above.
Construction of a shuttle vector for transformation of B.
burgdorferi B313
The HcpA encoding hcpA gene including its native promoter
region was amplified by PCR using primers BrTBam and BrTSph.
The resulting amplicon was cloned into pBSV2 yielding shuttle
vector pBR [29]. Transformation of B. burgdorferi B313 and
characterization of transformants was previously described [30].
Expression of HcpA of post-transformation B. burgdorferi B313 was
determined by Western blot using mAb BR-1 and sheep anti
mouse peroxidase-conjugated secondary Ab.
High-passage, non-infectious B. burgdorferi strain B313 were
grown in 100 ml BSK medium and harvested at mid exponential
phase (10
8 cells/ml). Electrocompetent cells were prepared as
described previously [30] with slight modifications. Briefly, 50 ml
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electroporated at 12.5 kV/cm in 2-mm cuvettes with 10 mgo f
plasmid DNA. For control purpose B. burgdorferi strain B313 cells
also were transformed with pBSV2 vector alone. Cells were
immediately diluted into 10 ml BSK medium and incubated
without antibiotic selection at 30uC for 48 to 72 h. Bacteria were
then diluted into 100 ml BSK medium containing kanamycin
(30 mg/ml) and 200 ml aliquots were plated into 96-well cell culture
plates (Corning) for selection of transformants. After three weeks,
wells were evaluated for positive growth by color change of the
medium, confirmed by dark-field microscopy for the presence of
motile spirochetes.
The hcpA genes of transformed B. burgdorferi B313 strain was
detected by PCR using primers BrF1 and BrR1 (Table 1) and
expression of the HcpA was determined by Western blot and
ligand affinity blot analysis.
Serum susceptibility testing of Borrelia strains
The serum susceptibility of B. recurrentis A1, B. burdorferi B313 and
transformed B. burgdorferi B313 was assessed using a survival assay.
Cells grown to mid-logarithmic phase were harvested, washed and
3610
7 spirochetes were resuspended in BSK-H medium (PAN)
supplemented with either 50% or 25% NHS or heat inactivated
serum (hiNHS) as indicated. Cells were incubated in Eppendorf
tubes at 30uC for 3 days. At day 0, 1, 2 and 3, cells were washed in
0.85% NaCl, transferred to microtiter plates and incubated with
SYTO9 (Molecular Probes, Invitrogen) as recommended by the
manufacturer. Subsequently, relative growth of spirochetes was
determined measuring the fluorescenceintensityat485 nm/530 nm
on a microtiter plate reader (Victor
2 plate reader, Perkin Elmer).
Production of monoclonal antibodies
Monoclonal antibodies directed against HcpA were generated
by immunization of Balb/c mice with the respective purified
recombinant protein according to a method as described
elsewhere [31]. For specific detection of CFHR-1, mAb JHD8
and for specific detection of His-tagged CFH deletion mutant
SCR19-20, mAb JHD7 were generated accordingly.
Nucleotide sequence deposition
The hcpA gene sequence encoding HcpA has been deposited in
the EMBL/GenBank databases under the following accession
numbers: FM946025.
Statistical analysis
Statistics were analyzed with the unpaired Student’s t-test, P
values less than 0.01 were considered significant.
Results
B. recurrentis spirochetes acquire complement regulators
CFH and CFHR-1
In light of previous experience that B. hermsii and B. burgdorferi
can specifically bind CFH via their outer surface lipoproteins
[8,11,32], B. recurrentis spirochetes were incubated with biotiny-
lated human CFH and analysed by flow cytometry. As seen in
Figure 1A, both, B. recurrentis strains (A1 and A17) and B. hermsii
HS1, but not B. burgdorferi B313, which lacks the CFH-binding
lipoprotein, were able to bind CFH. In addition, biotinylated
control protein, BSA, did not bind to any of the borrelial strains
(Fig. 1A). Binding of CFH to intact and viable B. recurrentis
Figure 1. Binding of CFH and CFHR-1 to the spirochetal surface. Binding of CFH to intact B. recurrentis cells was analyzed by flow cytometry
and immunofluorescence microscopy. (A) Spirochetes were incubated with biotinylated purified human CFH (bold lines) or as a negative control with
biotinylated BSA followed by PE-labeled streptavidin. B.hermsii HS1 and B. burgdorferi B313 were included as controls. (B) Cells were incubated with
purified human CFH followed by the CFH-specific mAb JHD7 and a Cy3-conjugated anti-mouse IgG. Images were obtained employing
epifluorescence microscopy. On the right panel the corresponding differential interference contrast image (DIC) is depicted. (C) Whole cell lysates of
B. recurrentis strain A1 and A17 (B.r. A1 and B.r. A17) were separated by Tris/Tricine SDS-PAGE, transferred to nitrocellulose membrane and incubated
with normal human serum. CFH binding was detected employing CFH specific mAb JHD7 and binding of CFHR-1 was analyzed using specific mAb
JHD8. For control, cell lysates of B. hermsii HS1 (B.h HS1) and B. burgdorferi B313 (B.b B313) were included.
doi:10.1371/journal.pone.0004858.g001
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mAb, JHD7 (Fig. 1B). By applying ligand affinity blot analysis for
detection of CFH- and CFHR-1 binding molecules, a protein of
approximately 17 kDa was detected in B. recurrentis but not in B.
burgdorferi B313 (Fig. 1C), termed human complement regulator(s)
and plasminogen binding protein A (HcpA) [8,9].
HcpA is a CFH, CFHR-1 and PLG binding protein
To isolate and further characterize HcpA, whole cell lysates of
B. recurrentis A1 were incubated with CFH and subsequently
treated with a goat anti-CFH immune serum. A resulting co-
precipitated protein of 17 kDa was analyzed by mass spectrometry
and peptides generated matched an open reading frame of 525 bp
on the genome of B. recurrentis A1 (unpublished data), designated
hcpA. Due to the presence of a spirochetal lipobox at its N-terminus
HcpA represents a putative outer surface lipoprotein [33]. The
deduced amino acid sequence exhibits 54% similarity with the
recently identified BhCRASP-1 of B. hermsii HS1 (Fig. 2) [8]. A
BLAST search detected another protein with significant homology
in the genome of B. turicatae, indicating that this protein is to be
found in other Borrelia species. To further elucidate the binding
properties of HcpA for complement regulators CFH and CFHR-1,
various N- and C-terminal deletion mutants of HcpA were
generated. Variants of the encoding hcpA gene lacking the
hydrophobic leader peptide and the indicated N- or C-terminal
regions were cloned and expressed as His-tagged fusion proteins in
E. coli (Fig. 3). Expression of each protein was confirmed by
immunoblot analysis using anti-His antiserum (Fig. 3A).
To assess binding of recombinant HcpA for CFH and CFHR-1,
ligand affinity blotting techniques and ELISA were employed in
combination with intact HcpA and various deletions thereof. CFH
and CFHR-1 only bound to full-length HcpA, but not to any of
the deletion mutants. This indicates that long-range intramolec-
ular interactions are involved in the formation of the CFH and
CFHR-1 binding site rather than linear peptide sequences
(Fig. 3A). Furthermore, full-length and mutant HcpA proteins
were analyzed for binding of human PLG using ELISA. Full-
length HcpA (residues 18 to 175) as well as the truncated versions
bound PLG (Fig. 3B), thus indicating that the binding site for PLG
is localized to the central domain of HcpA. Together, these data
suggest that CFH and PLG bind to distinct, non-overlapping
domains of the HcpA molecule (Fig. 3C). To verify this
assumption, competition assays were performed using immobilized
HcpA and increasing amounts of PLG or CFH (up to 100 mg/ml)
in combination with constant amounts of CFH (2 mg/ml) or PLG
(10 mg/ml), respectively. As shown in Fig. 3D, PLG did not
compete with CFH for binding to HcpA even at high
concentrations (100 mg/ml). Vice versa, using up to 100 mg/ml
of CFH no inhibition of PLG binding to HcpA could be observed.
To map the binding domain of CFH that interacts with HcpA,
recombinant deletion constructs of CFH representing SCRs 8-10,
SCRs 15-10, SCRs 19-20, and SCRs 1-7/FHL-1 were employed.
HcpA showed strong binding to CFH and deletion constructs
CFHSCR8-20, CFHSCR15-20, CFHSCR19-20, as well as CFHR-1.
Construct CFHL-1 (CFHSCR1-7) did not bind to HcpA, indicating
that the most C-terminal domains (SCR19-20) of CFH are
involved in binding (Fig. 4A). We next conducted surface plasmon
resonance analyses, a more physiological assay system, to further
define the CFH domain interacting with HcpA. CFH and deletion
constructs CFHSCR8-20, CFHSCR15-20 and CFHSCR19-20 bound to
immobilized HcpA with similar intensity (Fig. 4B). However, in
the absence of SCR20, represented by the deletion construct
CFHSCR15-19, binding to HcpA was completely abrogated
(Fig. 4B). As indicated by the schematic representation, domain
SCR20 of CFH displays 97% sequence similarity to the SCR5 of
CFHR-1 (Fig. 4C) [7]. Therefore it is assumed that the binding
region of CFHR-1 for HcpA is located in the C-terminus,
accordingly.
HcpA is exposed on the outer surface of B. recurrentis
To determine whether HcpA is exposed on the outer surface of
B. recurrentis immunofluorescence microscopy was performed.
Intact B. recurrentis spirochetes were incubated with the HcpA
specific mAb BR-1 followed by a Cy3-conjugated secondary
antibody (Fig. 5A, left panels). B. recurrentis expressed HcpA on its
outer surface and the staining showed a patchy distribution.
Mouse mAb LA21 directed against the periplasmic flagellin was
used as an internal control to confirm that the fragile spirochetal
outer membrane was intact (right panels). To further verify surface
localization of HcpA, B. recurrentis spirochetes were pre-treated
with either proteinase K or trypsin, lysed, separated by SDS-
PAGE and assayed by Western blotting. Fig. 5B demonstrates a
significant reduction of HcpA after 2 h of incubation with trypsin
at concentrations $12.5 mg/ml, whereas treatment with protein-
ase K at low concentrations ($3.125 mg/ml) resulted in complete
degradation. Signal intensity observed for flagellin remained
unchanged, indicating that periplasmic flagella were not affected
by proteolytic digestion. These data strongly suggest that HcpA is
exposed on the outer surface of B. recurrentis.
Figure 2. HcpA exhibits 54% amino acid sequence similarity to BhCRASP of B. hermsii HS1.
doi:10.1371/journal.pone.0004858.g002
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PLoS ONE | www.plosone.org 5 March 2009 | Volume 4 | Issue 3 | e4858Figure 3. Binding of CFH, CFHR-1 and PLG to HcpA. (A) Purified recombinant HcpA protein and various deletion mutants were separated by
SDS-PAGE and transferred to nitrocellulose. Membranes were incubated with a monoclonal anti-His-tag mAb (upper panel). CFH and CFHR-1 binding
capabilities were analyzed by ligand affinity blotting utilizing normal human serum and goat anti-CFH immune serum (middle panel) or the CFHR-1
specific mAb JHD8 (lower panel). (B) Microtiter plates were coated with full-length recombinant HcpA and the indicated deletion mutants,
respectively, and incubated with CFH, normal human serum (as source for CFHR-1) or PLG. Binding was detected using goat anti-CFH, the CFHR-1
specific mAb JHD8 or goat anti-PLG immune serum followed by the respective peroxidase-conjugated IgGs. (C) Diagrammatic representation of
native and expressed recombinant HcpA proteins and their binding characteristics for serum proteins CFH, CFHR-1 and PLG as determined by ligand
affinity blot analysis and ELISA. Numbers refer to amino acid residues. (D) Dose dependent binding of CFH and PLG by HcpA. A competition inhibition
assay was performed, adding different amounts of PLG or CFH to inhibit the binding of 2 mg/ml CFH (left panel) or 10 mg/ml PLG (right panel) to
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To assess whether HcpA-bound CFH maintains its complement
regulatory function, cofactor activity of the attached CFH was
analyzed by measuring factor I-mediated conversion of C3b to
iC3b. To this end, CFH was attached to immobilized HcpA and
incubated with C3b and factor I. As shown in Figure 6A, HcpA-
bound CFH efficiently mediated C3b conversion as indicated by
the appearance of C3b cleavage products (68, 46 and 43 kDa a9-
chain). Incubation of immobilized HcpA alone had no effect on
C3b conversion under similar conditions. Next we determined
whether CFH also retains its cofactor activity after previous
binding to B. recurrentis. Accordingly, spirochetes were pre-treated
with CFH and after intensive washings, incubated with factor I
and C3b. Lysates were separated by SDS-PAGE and C3b
cleavage products were detected by Western blotting. Surface-
bound CFH retained cofactor activity as indicated by the presence
of representative C3b inactivation products (Fig. 6B). B. recurrentis
spirochetes alone did not promote cleavage of C3b demonstrating
that B. recurrentis lack endogenous C3b cleaving activity and
cofactor activity for cleavage. Thus, binding of CFH to the surface
of B. recurrentis renders them resistant to complement attack.
Surface bound PLG is processed by host-derived
plasminogen activators to plasmin, cleaves fibrinogen
and exhibits anti-opsonic activities
To assess whether B. recurrentis-attached PLG can be processed
to active plasmin, spirochetes were pre-treated with PLG and
subsequently incubated with the exogenous human plasminogen
activator uPA. As shown in Figure 7A, B. recurrentis-attached PLG
was readily processed by exogenous uPA. In contrast, only
marginal plasmin activity was observed in the presence of
tranexamic acid, a competitive inhibitor of the lysine-binding site
of PLG. These data demonstrate that spirochetal surface-bound
PLG is accessible for uPA, and that processed plasmin retains its
proteolytic activity. No plasmin was generated from surface-bound
PLG in the absence of uPA, indicating that spirochetes do not
express endogenous plasminogen activators. Similar findings were
observed when recombinant HcpA was coated onto microtiter
plates supporting the notion that HcpA-bound PLG can be
processed to stable functional active plasmin (Fig. 7B).
The proteolytic activity of HcpA-bound plasmin was further
analyzed by its ability to cleave fibrinogen. When incubated with
HcpA-bound plasmin, fibrinogen was degraded to low molecular
mass fragments, as assessed by Western blotting (Fig. 7C). In the
absence of either PLG or uPA, no fibrinogen degradation was
observed. Furthermore, the addition of the plaminogen inhibitor
tranexamic acid to the reaction mixture abrogated the respective
proteolytic activity (data not shown).
Upon activation of complement by bacterial pathogens C3b is
covalently attached to the target surfaces and together with the
cleavage products, such as iC3b, the C3b molecules opsonize the
pathogenic organisms for phagocytosis. To assess whether plasmin
bound to HcpA is able to degrade C3b deposited on the cell
surface of B. recurrentis a C3b deposition and degradation assay
based on whole-cell ELISA was performed. Spirochetes were
immobilized onto microtiter plates and treated with human serum
and PLG. After extensive washing B. recurrentis-bound PLG was
activated by uPA and deposition of C3b molecules on the
spirochetal cell surface was monitored. B. recurrentis-bound active
plasmin led to a dramatic decrease of C3b molecules on the
spirochetal surface when compared to control spirochetes cultured
either with buffer alone, or those pre-treated with PLG in the
presence of tranexamic acid (Fig. 8). Thus, B. recurrentis cell surface-
bound plasmin exhibits anti-opsonic properties by cleaving C3b
molecules.
HcpA confers resistance to complement-mediated killing
To further verify the significance of HcpA of B. recurrentis for
complement resistance and removal of C3b from the bacterial
surface the serum-sensitive B. burgdorferi B313 strain, lacking CFH
and CFHL-1 binding proteins was transformed with the shuttle
vector pBR containing the complete hcpA gene (B. burgdorferi B313/
Figure 4. Mapping of the CFH domain interacting with HcpA.
(A) Purified recombinant HcpA protein was separated by SDS-PAGE and
transferred to nitrocellulose membranes. The membrane strips were
incubated with either normal human serum (NHS), recombinant CFHL-1
(CFHSCR 1-7), several deletion constructs of CFH (CFHSCR8-20, CFHSCR15-20,
CFHSCR15-19,C F H SCR19-20) or recombinant CFHR-1 (CFHR-1). Bound
proteins were visualized using either polyclonal anti-CFH immune
serum (a-CFH) or mAb specific for SCR19-20 (JHD7) or CFHR-1 protein
(JHD8), respectively. (B) Binding of CFH and deletion mutants to HcpA
as analyzed by surface plasmon resonance. Recombinant HcpA was
immobilized to the surface of a sensor chip and CFH or various deletion
mutants (CFHSCR15-20, CFHSCR19-20, CFHSCR15-19) were applied in the fluid
phase. No binding was detectable for CFHSCR15-19 mutant. (C) Schematic
representation of the CFH, CFHL-1 and CFHR-1 protein. Complement
regulatory domains in SCR1-4 are shown in gray and the HcpA binding
region in SCR20 of CFH and the corresponding SCR5 of CFHR-1 are
highlighted in black with white fonts. SCR domains are aligned vertically
according to their amino acid sequence similarities.
doi:10.1371/journal.pone.0004858.g004
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analysis using an HcpA-specific mAb, BR-1. B. recurrentis A1 and
the transformed B313/pBR isolate, but not the CFH and CFHL-
1-deficient B. burgdorferi B313 mutant, expressed HcpA (Fig. 9A,
upper panel). HcpA expression on the cell surface of transformed
B. burgdorferi B313 strains was also detected by whole cell ELISA
(Fig. 4B). Moreover, the expressed HcpA protein bound CFH as
confirmed by ligand affinity blotting (Fig. 9A, middle panel). In
addition, we demonstrate that HcpA expressed on the surface of
transformed B. burgdorferi B313/pBR cells promotes degradation of
deposited C3b (Fig. 9C). To compare the susceptibility of B.
recurrentis A1, B313 and B313/pBR to complement-mediated
killing, the three strains were subjected to a human serum
sensitivity assay. Accordingly, B. burgdorferi B313/pBR, B. recurrentis
A1, and B. burgdorferi B313 were incubated in NHS or heat-
inactivated serum for up to three days. Spirochetal growth was
monitored by uptake of a nucleic acid dye. As shown in Figure 9D,
B. recurrentis A1 readily multiplied during the 72 h time interval in
normal human serum, demonstrating the pronounced resistance
to human serum of louse-borne relapsing fever spirochetes.
Serum-sensitive B. burgdorferi B313 as well as B313 spirochetes
containing the shuttle vector alone (data not shown) did not grow
under similar conditions, suggesting their susceptibility to
complement-mediated lysis (Fig. 9E). In contrast, B313/pBR
expressing HcpA survived and multiplied in human serum. B.
burgdorferi B313 and the transformed B313/pBR isolate showed
similar growth rates when cultured in heat-inactivated human
serum. These findings strongly suggest that HcpA is required for
resistance of B. recurrentis to complement-mediated killing.
Discussion
The present results demonstrate for the first time that the
etiologic agent of louse-borne relapsing fever, B. recurrentis, express
a novel multifunctional surface lipoprotein, termed HcpA. By
exploiting host proteins, HcpA simultaneously confers resistance to
complement attack and opsonization, and in addition, imparts an
increased potential to invade host tissues. We show that B.
recurrentis can bind via its surface expressed HcpA molecule to
human complement regulators, i.e. CFH as well as CFHR-1, and
in parallel to plasminogen/plasmin. The finding that host-derived
factors retain their functional activities, when simultaneously
bound to the surfaces of the pathogen underscores the high
virulence potential of B. recurrentis and makes HcpA a promising
target for therapeutic treatment of severe louse-borne relapsing
fever [21,34,35,36,37,38].
Our data extent previous findings on a related CFH receptor
expressed by tick-borne relapsing fever B. hermsii spirochetes,
including the observation that surface bound CFH facilitates factor
I-mediated cleavage of C3b and is critical for immune evasion of
these and other pathogens [8,9]. In fact, CFH binding has also
been reported for a number of human pathogens, such as S.
pyogenes (group A streptococcus) [39], Neisseria gonorrhoeae [40], S.
pneumoniae [41,42], Borrelia burgdorferi [24,43], Candida albicans [44]
and other relapsing fever spirochetes [9,45,46]. Recombinant
HcpA specifically binds CFH and/or CFHR-1 and in addition
plasminogen, however via different binding domains. The CFH
binding site of HcpA was determined by using mutants with either
N-terminal (HcpA48-175, HcpA78-175) or C-terminal (HcpA18-145,
HcpA18-115) truncations. All mutant of HcpA caused complete
abrogation of CFH binding. These data suggest that the
determinants required for CFH binding are defined by confor-
mation rather than contiguous linear elements. This finding is
reminiscent of the observed CFH binding capabilities for B.
burgdorferi BbCRASP-1 and BbCRASP-3 [11,32,46,47]. In con-
trast, binding of PLG to HcpA was not affected by any of the
indicated truncations of the HcpA protein, demonstrating that
PLG and CFH interact with distinct HcpA domains and suggest
that both host proteins can bind simultaneously to HcpA. This
assumption is supported by our findings that PLG and CFH bind
independently and coordinately to immobilized HcpA and do not
Figure 5. Surface localization of HcpA. (A) Immunofluorescence analysis of B.recurrentis A1 after incubation with a mAb specific for HcpA (BR-1)
(left panels) or a flagellin-specific mAb (LA21, right panels) followed by rabbit anti-mouse Cy3-conjugated IgG. Corresponding differential interference
contrast images are shown in the lower panels. The images were obtained as described above. (B) Proteinase K and trypsin treatment affects surface
expression of native HcpA. B. recurrentis cells were incubated with the indicated concentrations of proteinase K and trypsin, lysed, immunoblotted,
and probed with either anti-HcpA mAb BR-1 (upper panel) or with anti-flagellin mAb LA21 (lower panel).
doi:10.1371/journal.pone.0004858.g005
Figure 6. Cofactor activity of CFH bound to either HcpA or
intact B. recurrentis spirochetes. Functional activity of CFH was
analyzed by measuring factor I-mediated conversion of C3b to iC3b.
CFH bound to HcpA coated microtiter plates (A) or to the surface of
intact B. recurrentis spirochetes (B) was incubated with C3b and factor I.
Reaction mixtures were separated by SDS-PAGE and transferred to
nitrocellulose membrane. C3b degradation products were evaluated by
detection of a9-chain cleavage fragments of 68, 46 and 43 kDa using
biotinylated rabbit anti-C3c IgG followed by peroxidase-conjugated
streptavidin. Purified iC3b was included as control.
doi:10.1371/journal.pone.0004858.g006
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of CFH and PLG to immobilized HcpA it is to be expected that
both host proteins similarly bind to HcpA expressed on the outer
surface of B. recurrentis. Further studies are needed to elucidate the
possibility that binding of CFH and PLG to the surface of B.
recurrentis may be involved in certain pathologies of the central
nervous system.
Plasma adsorption experiments and surface plasmon resonance
analyses clearly demonstrate that binding of CFH to HcpA is
exclusively associated with its C-terminal domain, SCR20. This
finding is further substantiated by the fact that HcpA bound
CFHR-1, another member of the factor H family that exhibits an
almost identical (97%) C-terminal short consensus repeat domain
[7]. Thus, the ability of the pathogen to coordinately bind CFH
and/or CFHR-1 to HcpA most probably adds to the virulence of
B. recurrentis by establishing its resistance to complement attack,
even under conditions when the human complement regulators
are differentially regulated.
Figure 7. Activation and proteolytic activity of HcpA- and B.
recurrentis-bound plasmin(ogen). Intact B. recurrentis organisms (A)
or recombinant HcpA (B) were incubated with PLG. Bound PLG was
converted into plasmin by uPA addition and plasmin activity was
measured using the chromogenic substrate D-Val-Leu-Lys 4-nitroanilide
dihydrochloride (S-2251). uPA mediated PLG activation was inhibited by
tranexamic acid (TA). Substrate cleaving was monitored by measure-
ment of the absorbance at 405 nm for up to 6 hrs. Mean of triplicates 6
SEM is shown. (C) Degradation of fibrinogen by HcpA-bound plasmin.
HcpA coated microtiter plates were incubated with PLG, subsequently
fibrinogen and uPA were added. The reaction mixtures were separated
by SDS-PAGE, transferred to nitrocellulose and probed with rabbit anti-
fibrinogen followed by peroxidase-conjugated IgG for detection of a, b
and c chains (67, 57 and 47 kDa) and the small-size degradation
products of fibrinogen.
doi:10.1371/journal.pone.0004858.g007
Figure 8. Degradation of deposited C3b by acquiring plasmin
on the surface of B. recurrentis. Spirochetes were immobilized onto
microtiter plates and incubated with 10% NHS as source for C3b.
Washed bacteria were treated with PLG in the presence or absence of
tranexamic acid (TA) and bound PLG was activated by uPA. Deposited
C3b was detected using biotinylated anti-C3c IgG followed by
peroxidase-conjugated streptavidin. C3b deposition is expressed as
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of the alternative complement pathway that binds to C3b, inhibits
the C5 convertase activity and interferes with C5b surface
deposition and membrane attack complex formation (Heinen et
al., unpublished). In this context it is of interest that HcpA is also
capable of binding another member of the factor H family, i.e.
CFHR-2, whose function is yet to be disclosed [7]. The present
data show that HcpA-bound CFH retains its regulatory capacity
and controls both C3b deposition and C3-convertase activity,
resulting in enhanced complement regulatory activity. This
process is expected to increase resistance of louse-borne relapsing
fever spirochetes to complement attack, an assumption supported
by our previous findings with B. hermsii.
There is ample evidence suggesting that binding of PLG to
bacterial surfaces, including spirochetes, is critical for their invasive
potential and persistance [9,17,48]. B. recurrentis binds PLG and
upon processing to enzymatically active plasmin by human uPA
the surface bound protease is shown to degrade the physiological
substrate fibrinogen. Together with the finding that PLG-coated
B. recurrentis also bind to the PLG receptors on endothelium cells,
our results suggest that spirochetes exploit their increased
proteolytic capacity to breach tight junctions of endothelium,
cross basement membranes, and to initiate patho-physiological
processes in the affected organs [48]. The finding that in
accordance to the related Lyme disease spirochetes, B. recurrentis
bind PLG and can disseminate from the blood to many distant
Figure 9. Ectopic expression of HcpA in serum-sensitive B. burgdorferi B313. (A) Expression of HcpA by transformed B. burgdorferi B313 was
assessed using immunoblot analysis. Whole cell lysates were separated by SDS-PAGE, transferred to nitrocellulose and probed with mAb BR-1 (upper
panel) or analyzed for CFH binding by incubation with NHS and a CFH-specific mAb (JHD7, middle panel) followed by peroxidase conjugated IgG. For
control, a flagellin-specific antibody (LA21) was used (lower panel). (B) Surface expression of HcpA as analyzed by whole cell ELISA using mAb BR-1. As
control, a flagellin-specific mAb LA21 was employed. (C) C3b deposition on the surface of B. burgdorferi B313/pBR cells incubated with 10% NHS was
determined using a whole cell ELISA as described above. Values represent the mean of triplicates6SEM. *, P,0.0001. To investigate serum
susceptibility to human serum B. recurrentis A1 (D), B.burgdorferi B313 and transformed B. burgdorferi B313/pBR cells (E) were incubated with the
indicated concentrations of NHS (dashed line) or heat-inactivated serum (solid line) at 30uC for 3 days. Cells were stained with a nucleic acid dye and
the relative growth was determined by measurement of the fluorescence intensities. Values represent the mean6SEM of a single experiment
performed in triplicate that is representative of three independent experiments. *, P,0.01; **, P,0.001; ***P,0.0001.
doi:10.1371/journal.pone.0004858.g009
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mechanisms could be involved [47].
It was recently shown that Staphylococcus aureus employs host
plasmin to degrade both, surface-bound IgG as well as C3b, and
thereby confers resistance to innate and adaptive immune defense
processes [49]. Our corresponding finding that HcpA bound
plasmin leads to a decrease of C3b molecules on the surface of B.
recurrentis may represent a novel mechanism, by which spirochetes
interfere with C3b deposition on their cell surface and moreover
could escape phagocytosis. In line with this assumption, trans-
formed B. burgdorferi B313/pBR cells exhibit a significant reduction
of C3b molecules deposited on their surface as compared to the
parental B. burgdorferi B313 strain. Depleted C3b at the bacterial
surface correlates with lowering phagocytic activity of human
neutrophils [49]. Modulation of opsonic molecules such as C3b
seems an ideal strategy for bacterial survival and may account for
the extraordinary virulence of B. recurrentis. Furthermore, it was
recently demonstrated that B. recurrentis acquire C4b-binding
protein, another regulator of the classical pathway of complement
activation on their surface [21]. However, in preliminary
experiments binding of HcpA to C4b-binding protein could not
be observed. In contrast, a novel 45 kDa protein was shown to
strongly interact with C4b-binding protein suggesting that in B.
recurrentis at least two different receptors for binding of the two
complement regulators, CFH and C4b-binding protein, are
expressed (unpublished).
Although the biological significance of HcpA expression by B.
recurrentis has still to be elucidated, the present finding that the B.
burgdorferi B313 mutant, deficient in CFH receptors, resists
complement-mediated killing and following transfection with hcpA
strongly suggests the involvement of HcpA in immune evasion of
B. recurrentis. Recently, ectopic expression of the B. burgdorferi
BbCRASP-1 lipoprotein on the surface of a serum-sensitive
Borrelia strain imparts resistance of the transformed isolate to
human serum [12,30,50]. In the murine model of Lyme disease
the precise role of another complement binding protein,
BbCRASP-2, was explored and the results of this study suggested
that BbCRASP-2 function is dispensable for infectivity [51].
However, studies of the biology of B. recurrentis and louse-borne
relapsing fever have been hampered by the lack of an animal
model. Further investigations are needed to fully examine the
complex interplay between B. recurrentis, serum sensitivity, and the
role of HcpA in the pathogenesis of the disease.
In summary, this is the first study showing the simultaneous and
non-competitive binding of CFH and PLG to the outer surface
protein HcpA of B. recurrentis, the agent of louse-borne relapsing
fever. Our finding that HcpA is a multifunctional virulence factor
with the potential to simultaneously mediate innate immune
evasion and degradation of extracellular matrix components
significantly adds to our understanding of the pathological
processes underlying louse-borne relapsing fever. Moreover, the
presented data support the concept of exploitation of host factors
as suitable survival strategies.
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